Influenza Vaccine Market Global Demand, Innovation Trends, and Growth Opportunities (2025-2031)

Los Angeles, United States - QY Research has released a new publication titled "Global Influenza Vaccine Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031." This comprehensive study provides an in-depth evaluation of the worldwide Influenza Vaccine industry, uncovering the major forces influencing market growth and delivering high-value insights for investors, industry leaders, and strategic decision-makers. The report examines critical elements such as market dynamics, evolving technologies, segmentation trends, regional developments, and the competitive landscape. With data backed by rigorous research and expert interpretation, it offers an authoritative guide to understanding the macroeconomic and microeconomic factors reshaping the global market.

The global market for Influenza Vaccine was estimated to be worth US$ 9135 million in 2024 and is forecast to a readjusted size of US$ 13500 million by 2031 with a CAGR of 5.5% during the forecast period 2025-2031.

Download FREE Sample PDF (Including Full TOC, Tables & Charts): https://qyresearch.in/request-sample/pharma-healthcare-influenza-vaccine-global-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Market Overview -

The study provides verified historical data and forward-looking projections, offering readers a clear understanding of how the Influenza Vaccine market is expected to expand through 2031. Using accurate and validated data sources, the report answers key questions related to market size, growth patterns, strategic initiatives, and future investment potential.

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Market Drivers & Challenges -

Market Driver:

The Influenza Vaccine market is driven by the rising global awareness of flu prevention and increasing government initiatives to promote vaccination programs. Seasonal influenza poses a significant public health burden, leading to hospitalizations and fatalities, particularly among high-risk populations such as the elderly, young children, and immunocompromised individuals. Governments and health organizations, including the WHO and CDC, actively support annual flu vaccination campaigns to reduce disease transmission. Additionally, advancements in vaccine technology, such as cell-based and recombinant influenza vaccines, are improving vaccine efficacy and production efficiency, further driving market growth.

Market Challenge:

Despite its importance, the Influenza Vaccine market faces challenges related to vaccine hesitancy, manufacturing constraints, and viral mutations. Public skepticism regarding vaccine safety and effectiveness, fueled by misinformation, hampers vaccination rates in some regions. Additionally, influenza viruses undergo frequent genetic mutations, requiring annual vaccine updates and posing challenges in predicting dominant strains. Manufacturing influenza vaccines is also time-sensitive, as traditional egg-based production methods have limitations in scalability and response speed during pandemics. These factors can impact supply chain stability and overall vaccine accessibility.

Global key players of Pandemic Influenza Vaccine include Sanofi, CSL and GSK, etc. The top five players hold a share about 80%. North America is the largest market, has a share about 50%.

Major Company Included: -

Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics

The competitive section of the report provides essential insights needed for companies to strengthen their market positioning. It highlights the strategies adopted by leading players-covering innovation, pricing models, marketing channels, distribution networks, and regional expansion. This evaluation enables market participants to identify competitive advantages and understand challenges that may affect their long-term performance.

Market Segmentation -

The report presents a granular breakdown of the global Influenza Vaccine market, emphasizing CAGR, market share, future potential, and emerging trends across each segment.

By Type

Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine

By Application

6 Months to 3 Years
greater than 3 Years

This segmentation helps identify high-growth niches and valuable investment opportunities across product types and applications.

Regional Analysis -

The report offers a detailed geographic assessment covering four major regions and key contributing countries. Insights include consumption patterns, production levels, market share distribution, and long-term growth prospects.

North America

United States

Canada
Mexico
Latin America
Brazil

Other key regional markets

Asia-Pacific
China
Japan
India
South Korea
ASEAN Countries

Europe, Middle East & Africa (EMEA)

Germany
France
United Kingdom
GCC Countries
African Nations

The analysis spans from 2024 (base year) to 2031 (forecast period).

Pre-Order / Enquiry Link: https://qyresearch.in/pre-order-inquiry/pharma-healthcare-influenza-vaccine-global-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Why This Report Is Essential -

✔ Complete Historical & Forecast Analysis (2020-2031)
✔ Detailed Segmentation by Type, Application & Region
✔ In-Depth Competitive Landscape & Company Profiling
✔ Drivers, Restraints & Market Dynamics Explained
✔ Expert Insights to Support Strategic Planning

Report Objectives -

Measure the global Influenza Vaccine market size (value & volume).

Accurately analyze market shares, consumption trends, and segment performance.

Examine major market dynamics and industry-shaping forces.

Identify and discuss key production, revenue, and sales trends.

Profile top market players and evaluate their competitive strategies.

Review manufacturing practices, pricing structures, and cost trends.

Compare regional and national market performance across key geographies.

Forecast segment-wise and region-wise growth opportunities through 2031.

Key Questions Answered in the Report -

What is the size and estimated growth rate of the global and regional Influenza Vaccine market?

Which countries are expected to display the strongest growth?

Which region will dominate the market throughout the forecast period?

What are the main factors driving or restraining market expansion?

What technological advancements are shaping future demand?

Where are the key opportunities for new entrants and established players?

Which companies currently hold the highest market share?

How will market dynamics evolve from 2025 to 2031?

Table of Contents - Major Key Points:

1 Market Overview
1.1 Influenza Vaccine Product Introduction
1.2 Global Influenza Vaccine Market Size Forecast
1.2.1 Global Influenza Vaccine Sales Value (2020-2031)
1.2.2 Global Influenza Vaccine Sales Volume (2020-2031)
1.2.3 Global Influenza Vaccine Sales Price (2020-2031)
1.3 Influenza Vaccine Market Trends & Drivers
1.3.1 Influenza Vaccine Industry Trends
1.3.2 Influenza Vaccine Market Drivers & Opportunity
1.3.3 Influenza Vaccine Market Challenges
1.3.4 Influenza Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Influenza Vaccine Players Revenue Ranking (2024)
2.2 Global Influenza Vaccine Revenue by Company (2020-2025)
2.3 Global Influenza Vaccine Players Sales Volume Ranking (2024)
2.4 Global Influenza Vaccine Sales Volume by Company Players (2020-2025)
2.5 Global Influenza Vaccine Average Price by Company (2020-2025)
2.6 Key Manufacturers Influenza Vaccine Manufacturing Base and Headquarters
2.7 Key Manufacturers Influenza Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Influenza Vaccine
2.9 Influenza Vaccine Market Competitive Analysis
2.9.1 Influenza Vaccine Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Influenza Vaccine Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Vaccine as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Trivalent Influenza Vaccine
3.1.2 Quadrivalent Influenza Vaccine
3.2 Global Influenza Vaccine Sales Value by Type
3.2.1 Global Influenza Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Influenza Vaccine Sales Value, by Type (2020-2031)
3.2.3 Global Influenza Vaccine Sales Value, by Type (%) (2020-2031)
3.3 Global Influenza Vaccine Sales Volume by Type
3.3.1 Global Influenza Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Influenza Vaccine Sales Volume, by Type (2020-2031)
3.3.3 Global Influenza Vaccine Sales Volume, by Type (%) (2020-2031)
3.4 Global Influenza Vaccine Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 6 Months to 3 Years
4.1.2 > 3 Years
4.2 Global Influenza Vaccine Sales Value by Application
4.2.1 Global Influenza Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Influenza Vaccine Sales Value, by Application (2020-2031)
4.2.3 Global Influenza Vaccine Sales Value, by Application (%) (2020-2031)
4.3 Global Influenza Vaccine Sales Volume by Application
4.3.1 Global Influenza Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Influenza Vaccine Sales Volume, by Application (2020-2031)
4.3.3 Global Influenza Vaccine Sales Volume, by Application (%) (2020-2031)
4.4 Global Influenza Vaccine Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Influenza Vaccine Sales Value by Region
5.1.1 Global Influenza Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Influenza Vaccine Sales Value by Region (2020-2025)
5.1.3 Global Influenza Vaccine Sales Value by Region (2026-2031)
5.1.4 Global Influenza Vaccine Sales Value by Region (%), (2020-2031)
5.2 Global Influenza Vaccine Sales Volume by Region
5.2.1 Global Influenza Vaccine Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Influenza Vaccine Sales Volume by Region (2020-2025)
5.2.3 Global Influenza Vaccine Sales Volume by Region (2026-2031)
5.2.4 Global Influenza Vaccine Sales Volume by Region (%), (2020-2031)
5.3 Global Influenza Vaccine Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Influenza Vaccine Sales Value, 2020-2031
5.4.2 North America Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Influenza Vaccine Sales Value, 2020-2031
5.5.2 Europe Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Influenza Vaccine Sales Value, 2020-2031
5.6.2 Asia Pacific Influenza Vaccine Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Influenza Vaccine Sales Value, 2020-2031
5.7.2 South America Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Influenza Vaccine Sales Value, 2020-2031
5.8.2 Middle East & Africa Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Influenza Vaccine Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Influenza Vaccine Sales Value and Sales Volume
6.2.1 Key Countries/Regions Influenza Vaccine Sales Value, 2020-2031
6.2.2 Key Countries/Regions Influenza Vaccine Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Influenza Vaccine Sales Value, 2020-2031
6.3.2 United States Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Influenza Vaccine Sales Value, 2020-2031
6.4.2 Europe Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Influenza Vaccine Sales Value, 2020-2031
6.5.2 China Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.5.3 China Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Influenza Vaccine Sales Value, 2020-2031
6.6.2 Japan Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Influenza Vaccine Sales Value, 2020-2031
6.7.2 South Korea Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Influenza Vaccine Sales Value, 2020-2031
6.8.2 Southeast Asia Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Influenza Vaccine Sales Value, 2020-2031
6.9.2 India Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.9.3 India Influenza Vaccine Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Sanofi
7.1.1 Sanofi Company Information
7.1.2 Sanofi Introduction and Business Overview
7.1.3 Sanofi Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Sanofi Influenza Vaccine Product Offerings
7.1.5 Sanofi Recent Development
7.2 CSL
7.2.1 CSL Company Information
7.2.2 CSL Introduction and Business Overview
7.2.3 CSL Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 CSL Influenza Vaccine Product Offerings
7.2.5 CSL Recent Development
7.3 GSK
7.3.1 GSK Company Information
7.3.2 GSK Introduction and Business Overview
7.3.3 GSK Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 GSK Influenza Vaccine Product Offerings
7.3.5 GSK Recent Development
7.4 Viatris
7.4.1 Viatris Company Information
7.4.2 Viatris Introduction and Business Overview
7.4.3 Viatris Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Viatris Influenza Vaccine Product Offerings
7.4.5 Viatris Recent Development
7.5 AstraZeneca
7.5.1 AstraZeneca Company Information
7.5.2 AstraZeneca Introduction and Business Overview
7.5.3 AstraZeneca Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 AstraZeneca Influenza Vaccine Product Offerings
7.5.5 AstraZeneca Recent Development
7.6 Hualan Bio
7.6.1 Hualan Bio Company Information
7.6.2 Hualan Bio Introduction and Business Overview
7.6.3 Hualan Bio Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Hualan Bio Influenza Vaccine Product Offerings
7.6.5 Hualan Bio Recent Development
7.7 Changchun Institute of Biological
7.7.1 Changchun Institute of Biological Company Information
7.7.2 Changchun Institute of Biological Introduction and Business Overview
7.7.3 Changchun Institute of Biological Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Changchun Institute of Biological Influenza Vaccine Product Offerings
7.7.5 Changchun Institute of Biological Recent Development
7.8 Sinovac
7.8.1 Sinovac Company Information
7.8.2 Sinovac Introduction and Business Overview
7.8.3 Sinovac Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Sinovac Influenza Vaccine Product Offerings
7.8.5 Sinovac Recent Development
7.9 BCHT
7.9.1 BCHT Company Information
7.9.2 BCHT Introduction and Business Overview
7.9.3 BCHT Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 BCHT Influenza Vaccine Product Offerings
7.9.5 BCHT Recent Development
7.10 Jiangsu GDK
7.10.1 Jiangsu GDK Company Information
7.10.2 Jiangsu GDK Introduction and Business Overview
7.10.3 Jiangsu GDK Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Jiangsu GDK Influenza Vaccine Product Offerings
7.10.5 Jiangsu GDK Recent Development
7.11 KM Biologics
7.11.1 KM Biologics Company Information
7.11.2 KM Biologics Introduction and Business Overview
7.11.3 KM Biologics Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 KM Biologics Influenza Vaccine Product Offerings
7.11.5 KM Biologics Recent Development
8 Industry Chain Analysis
8.1 Influenza Vaccine Industrial Chain
8.2 Influenza Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Influenza Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Influenza Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

About Us:

QYResearch established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.

Contact Us:

Arshad Shaha | Marketing Executive

QY Research, INC.
315 Work Avenue, Raheja Woods,
Survey No. 222/1, Plot No. 25, 6th Floor,
Kayani Nagar, Yervada, Pune 411006, Maharashtra
Tel: +91-8669986909
Emails - arshad@qyrindia.com
Web - https://www.qyresearch.in

This release was published on openPR.